2024
Trends in breast cancer specific death by clinical stage at diagnoses between 2000-2017
Marczyk M, Kahn A, Silber A, Rosenblit M, Digiovanna M, Lustberg M, Pusztai L. Trends in breast cancer specific death by clinical stage at diagnoses between 2000-2017. Journal Of The National Cancer Institute 2024, djae241. PMID: 39348186, DOI: 10.1093/jnci/djae241.Peer-Reviewed Original ResearchBreast cancer-specific deathCancer-specific deathBreast cancerStage IAll-cause mortalityTemporal trendsStage I/II breast cancerHormone receptor-positiveNode-negative cancersPrimary tumor typeStage I/II diseaseMetastatic breast cancerStage II cancerBilateral cancerIV cancerFemale sexIV diseaseReceptor-positiveExcellent prognosisII cancerClinical stageTumor typesTreated patientsStage IIICancer
2021
How did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer?
Chagpar A, Lannin D, Mougalian S, Berger E, Gross C, Horowitz N, Sanft T, DiGiovanna M, Golshan M, Pusztai L. How did the COVID crisis affect use of neoadjuvant therapy for patients with breast cancer? Journal Of Clinical Oncology 2021, 39: e18708-e18708. DOI: 10.1200/jco.2021.39.15_suppl.e18708.Peer-Reviewed Original ResearchUse of NTNeoadjuvant therapyEarly pandemic periodBreast cancerNon-metastatic breast cancerPractice settingsEarly pandemicFlatiron Health databaseNeoadjuvant endocrine therapyTechnology-enabled abstractionSame period one yearSimilar clinicopathologic featuresLongitudinal electronic health recordsPeriod one yearElectronic health recordsTNBC subsetEndocrine therapyPatient ageTN patientsClinicopathologic featuresContemporary cohortClinical stageCancer clinicCancer managementHigh risk
2017
Duration of neoadjuvant endocrine therapy and breast cancer outcomes.
Mougalian S, Soulos P, Lannin D, Pusztai L, Gross C, Killelea B. Duration of neoadjuvant endocrine therapy and breast cancer outcomes. Journal Of Clinical Oncology 2017, 35: e12129-e12129. DOI: 10.1200/jco.2017.35.15_suppl.e12129.Peer-Reviewed Original ResearchNeoadjuvant endocrine therapyEndocrine therapyClinical stagePathologic stageNational Cancer Data BasePR-positive breast cancerHigher nodal stageNetwork cancer programsAdjuvant endocrine therapyMultiple comorbid conditionsBreast cancer outcomesPopulation of patientsType of surgeryPositive breast cancerSimilar response ratesNeoadjuvant chemotherapyUnderwent surgeryNodal stageComorbid conditionsCancer outcomesLarge tumorsCancer programsBreast cancerOlder womenPatients
2012
High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients
Holder AM, Gonzalez-Angulo AM, Chen H, Akcakanat A, Do KA, Fraser Symmans W, Pusztai L, Hortobagyi GN, Mills GB, Meric-Bernstam F. High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients. Breast Cancer Research And Treatment 2012, 137: 319-327. PMID: 23208590, PMCID: PMC3556743, DOI: 10.1007/s10549-012-2354-4.Peer-Reviewed Original ResearchConceptsRelapse-free survivalShorter relapse-free survivalBreast cancerOverall survivalPatient ageMultivariable analysisClinical stageSCD1 levelsSCD1 expressionTumor subtypesStearoyl-CoA desaturase 1 expressionTriple-negative breast cancerMartingale residual plotsPrimary breast cancerSurvival of patientsBreast cancer patientsClinical pathologic characteristicsTumor clinical stageDesaturase 1 expressionBreast cancer subtypesBreast cancer cell linesExpression levelsRole of SCD1Fine needle aspiratesOverexpression of SCD1
2008
Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers
Mazouni C, Arun B, André F, Ayers M, Krishnamurthy S, Wang B, Hortobagyi GN, Buzdar AU, Pusztai L. Collagen IV levels are elevated in the serum of patients with primary breast cancer compared to healthy volunteers. British Journal Of Cancer 2008, 99: 68-71. PMID: 18560403, PMCID: PMC2453019, DOI: 10.1038/sj.bjc.6604443.Peer-Reviewed Original ResearchConceptsCollagen IV levelsHealthy womenCancer patientsBreast cancerPreoperative chemotherapySerum levelsCollagen IVBaseline serum levelsSerum collagen IVPrimary breast cancerBreast cancer patientsSera of patientsMarkers of angiogenesisSandwich enzyme-linked immunoassayEnzyme-linked immunoassayCollagen IV concentrationVascular basement membraneClinical stageHER2 statusHealthy controlsSignificant further increaseHealthy volunteersPatientsChemotherapyStage II
2007
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L. Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy. Journal Of Clinical Oncology 2007, 25: 4414-4422. PMID: 17785706, DOI: 10.1200/jco.2007.10.6823.Peer-Reviewed Original ResearchConceptsDistant relapse-free survivalResidual cancer burdenHormone receptor statusNeoadjuvant chemotherapyHormone therapyPathologic responseReceptor statusCancer burdenResidual diseasePathologic American Joint CommitteeMultivariate Cox regression analysisAdjuvant hormone therapyBreast cancer burdenDifferent treatment cohortsPretreatment clinical stageAmerican Joint CommitteeCox regression analysisRelapse-free survivalSequential paclitaxelDistant relapseSame prognosisComplete responseNodal metastasisTreatment cohortsClinical stage
2005
Nomograms to Predict Pathologic Complete Response and Metastasis-Free Survival After Preoperative Chemotherapy for Breast Cancer
Rouzier R, Pusztai L, Delaloge S, Gonzalez-Angulo AM, Andre F, Hess KR, Buzdar AU, Garbay JR, Spielmann M, Mathieu MC, Symmans WF, Wagner P, Atallah D, Valero V, Berry DA, Hortobagyi GN. Nomograms to Predict Pathologic Complete Response and Metastasis-Free Survival After Preoperative Chemotherapy for Breast Cancer. Journal Of Clinical Oncology 2005, 23: 8331-8339. PMID: 16293864, DOI: 10.1200/jco.2005.01.2898.Peer-Reviewed Original ResearchMeSH KeywordsAnthracyclinesAntibiotics, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsChemotherapy, AdjuvantDecision Making, Computer-AssistedDisease-Free SurvivalFemaleFranceHumansInternetLogistic ModelsMiddle AgedMultivariate AnalysisNeoadjuvant TherapyNomogramsPaclitaxelPredictive Value of TestsProportional Hazards ModelsReproducibility of ResultsTexasConceptsDistant metastasis-free survivalPathologic complete responseMetastasis-free survivalPreoperative chemotherapyComplete responseCox proportional hazards regression modelProportional hazards regression modelsM.D. Anderson Cancer CenterPreoperative chemotherapy cyclesSchedule of paclitaxelCombination of paclitaxelEstrogen receptor statusHazards regression modelsMultivariate logistic regressionInstitut Gustave RoussyAnderson Cancer CenterInclusion of paclitaxelClinical prediction modelChemotherapy cyclesReceptor statusClinical stageClinical variablesHistologic gradeCancer CenterPrediction nomogram
2003
HER-2/neu testing in breast cancer.
Ross JS, Fletcher JA, Bloom KJ, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Hortobagyi GN. HER-2/neu testing in breast cancer. American Journal Of Clinical Pathology 2003, 120 Suppl: s53-71. PMID: 15298144, DOI: 10.1309/949fpq1aq3p0rlc0.Peer-Reviewed Original ResearchConceptsBreast cancerNeu testingNeu statusProspective clinical outcome studyTrastuzumab-based therapyMajor clinical trialsEarly clinical stagePredictors of responseClinical outcome studiesBreast cancer specimensAdvanced diseaseClinical responseClinical stageClinical trialsStandards of practiceCancer specimensImmunohistochemical analysisOutcome studiesPotential efficacyCancerSitu hybridization techniqueRecent evidenceTherapySitu hybridization methodExcellent results